ECSP067020A - Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica - Google Patents
Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéuticaInfo
- Publication number
- ECSP067020A ECSP067020A EC2006007020A ECSP067020A ECSP067020A EC SP067020 A ECSP067020 A EC SP067020A EC 2006007020 A EC2006007020 A EC 2006007020A EC SP067020 A ECSP067020 A EC SP067020A EC SP067020 A ECSP067020 A EC SP067020A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- alkyl
- optionally substituted
- hydrogen atom
- alkylidene
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000001118 alkylidene group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002070 alkenylidene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuesto que responde a la fórmula (1) en la que n puede tomar un valor de 1 a 6, -(C)n- representa un grupo alquilideno C1-6, opcionalmente sustituido con 1 a 4 sustituyentes; R1 representa un átomo de hidrógeno, un grupo alquilo C1-6, R2 representa un átomo de hidrógeno, un grupo alquilo C1-6 o cicloalquilo C3-6 opcionalmente sustituidos con 1 a 4 sustituyentes, B representa NR3R4, R3 y R4 representan, independientemente del otro, un grupo alquilo C1-6,un átomo de hidrógeno, o R3 y R4 representan juntos un grupo alquilideno C1-6, un grupo alquenilideno C2-8, un grupo alquilideno C1-3-O-alquilideno C1-3, o un grupo alquilideno C1-3-N(R5)-alquilideno C1-3, donde R5 representa un átomo de hidrógeno o un grupo alquilo C1-3 o alquilcarbonilo C1-6, pudiendo estos grupos alquilo C1-3 y alquilcarbonilo C1-6 estar sustituidos, o un aminociclo, unido pon un carbono al grupo -NR1-(C)n-, tal como aziridina, azetidina, pirrolidina, piperidina o morfolino, estando los grupos R3, R4, así como el aminociclo opcional mente sustituidos y el átomo de nitrógeno opcionalmente sustituido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0405607A FR2870846B1 (fr) | 2004-05-25 | 2004-05-25 | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| PCT/FR2005/001279 WO2005118547A1 (fr) | 2004-05-25 | 2005-05-24 | Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP067020A true ECSP067020A (es) | 2006-12-29 |
Family
ID=34944870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006007020A ECSP067020A (es) | 2004-05-25 | 2006-11-22 | Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US7833999B2 (es) |
| EP (1) | EP1753725B1 (es) |
| JP (1) | JP4861979B2 (es) |
| KR (1) | KR101176675B1 (es) |
| CN (1) | CN1956962B (es) |
| AR (1) | AR050250A1 (es) |
| AU (1) | AU2005250197B2 (es) |
| BR (1) | BRPI0511581A (es) |
| CA (1) | CA2565293C (es) |
| CR (1) | CR8735A (es) |
| CY (1) | CY1114240T1 (es) |
| DK (1) | DK1753725T3 (es) |
| DO (1) | DOP2005000103A (es) |
| EA (1) | EA010234B1 (es) |
| EC (1) | ECSP067020A (es) |
| ES (1) | ES2407140T3 (es) |
| FR (1) | FR2870846B1 (es) |
| GT (1) | GT200500126A (es) |
| HN (1) | HN2005000239A (es) |
| HR (1) | HRP20130431T1 (es) |
| IL (1) | IL179021A (es) |
| JO (1) | JO2877B1 (es) |
| MA (1) | MA28720B1 (es) |
| MX (1) | MXPA06013629A (es) |
| MY (1) | MY148980A (es) |
| NI (1) | NI200600279A (es) |
| NO (1) | NO338104B1 (es) |
| NZ (1) | NZ551509A (es) |
| PA (1) | PA8634501A1 (es) |
| PE (1) | PE20060273A1 (es) |
| PL (1) | PL1753725T3 (es) |
| PT (1) | PT1753725E (es) |
| SI (1) | SI1753725T1 (es) |
| SV (1) | SV2006002126A (es) |
| TN (1) | TNSN06356A1 (es) |
| TW (1) | TWI360540B (es) |
| UA (1) | UA84771C2 (es) |
| UY (1) | UY28917A1 (es) |
| WO (1) | WO2005118547A1 (es) |
| ZA (1) | ZA200609820B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8664245B2 (en) | 2009-06-26 | 2014-03-04 | Sanofi | Fumarate salts of a histamine H3 receptor antagonist |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
| CN101855211B (zh) | 2007-11-13 | 2013-06-12 | 大正制药株式会社 | 苯基吡唑衍生物 |
| TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
| BR112014013461A2 (pt) | 2011-12-08 | 2017-06-13 | Taisho Pharmaceutical Co Ltd | derivado de fenilpirrol |
| US20150045553A1 (en) | 2011-12-27 | 2015-02-12 | Taisho Pharmaceutical Co., Ltd | Phenyltriazole derivative |
| EP2647377A1 (en) * | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
| CN110642854A (zh) * | 2019-11-20 | 2020-01-03 | 成都克莱蒙医药科技有限公司 | 一种稠环化合物的多晶型、其组合物、制备方法及其应用 |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029273A1 (en) | 1993-06-09 | 1994-12-22 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| WO1997029092A1 (en) * | 1996-02-09 | 1997-08-14 | James Black Foundation Limited | Histamine h3 receptor ligands |
| PL343424A1 (en) | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
| JP2003500382A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子の阻害剤 |
| WO2002053558A1 (en) | 2001-01-02 | 2002-07-11 | F.Hoffman-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| JP2004532834A (ja) * | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| JP2003192660A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
| WO2003055848A2 (en) * | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
| WO2003076527A1 (en) | 2002-03-08 | 2003-09-18 | Sakata Inx Corp. | Treated pigment, use thereof, and compound for treating pigment |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2004019935A1 (en) * | 2002-08-29 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
| MXPA06004005A (es) | 2003-10-08 | 2006-06-28 | Vertex Pharma | Moduladores de transportadores con casete de union con atp. |
| US20070099938A1 (en) | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
| FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| EP1630158A1 (en) | 2004-08-18 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
| ES2257168B1 (es) | 2004-08-18 | 2007-06-01 | Laboratorios Del Dr Esteve, S.A. | Ligandos del receptor 5-ht7. |
| US20080261999A1 (en) | 2005-03-04 | 2008-10-23 | Fionna Mitchell Martin | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists |
| EP1790646A1 (fr) | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
-
2004
- 2004-05-25 FR FR0405607A patent/FR2870846B1/fr not_active Expired - Lifetime
-
2005
- 2005-05-23 JO JO200571A patent/JO2877B1/en active
- 2005-05-23 HN HN2005000239A patent/HN2005000239A/es unknown
- 2005-05-23 PE PE2005000566A patent/PE20060273A1/es not_active Application Discontinuation
- 2005-05-23 AR ARP050102107A patent/AR050250A1/es not_active Application Discontinuation
- 2005-05-24 UA UAA200613640A patent/UA84771C2/uk unknown
- 2005-05-24 WO PCT/FR2005/001279 patent/WO2005118547A1/fr not_active Ceased
- 2005-05-24 GT GT200500126A patent/GT200500126A/es unknown
- 2005-05-24 BR BRPI0511581-7A patent/BRPI0511581A/pt not_active Application Discontinuation
- 2005-05-24 SI SI200531708T patent/SI1753725T1/sl unknown
- 2005-05-24 JP JP2007514007A patent/JP4861979B2/ja not_active Expired - Lifetime
- 2005-05-24 ZA ZA200609820A patent/ZA200609820B/xx unknown
- 2005-05-24 ES ES05772938T patent/ES2407140T3/es not_active Expired - Lifetime
- 2005-05-24 KR KR1020067024780A patent/KR101176675B1/ko not_active Expired - Fee Related
- 2005-05-24 CA CA2565293A patent/CA2565293C/fr not_active Expired - Fee Related
- 2005-05-24 MX MXPA06013629A patent/MXPA06013629A/es active IP Right Grant
- 2005-05-24 MY MYPI20052337A patent/MY148980A/en unknown
- 2005-05-24 HR HRP20130431TT patent/HRP20130431T1/hr unknown
- 2005-05-24 PT PT57729386T patent/PT1753725E/pt unknown
- 2005-05-24 CN CN200580016856.7A patent/CN1956962B/zh not_active Expired - Lifetime
- 2005-05-24 TW TW094116907A patent/TWI360540B/zh not_active IP Right Cessation
- 2005-05-24 UY UY28917A patent/UY28917A1/es not_active Application Discontinuation
- 2005-05-24 NZ NZ551509A patent/NZ551509A/en not_active IP Right Cessation
- 2005-05-24 PL PL05772938T patent/PL1753725T3/pl unknown
- 2005-05-24 EP EP05772938A patent/EP1753725B1/fr not_active Expired - Lifetime
- 2005-05-24 DK DK05772938.6T patent/DK1753725T3/da active
- 2005-05-24 EA EA200602176A patent/EA010234B1/ru not_active IP Right Cessation
- 2005-05-24 AU AU2005250197A patent/AU2005250197B2/en not_active Ceased
- 2005-05-24 SV SV2005002126A patent/SV2006002126A/es active IP Right Grant
- 2005-05-25 DO DO2005000103A patent/DOP2005000103A/es unknown
- 2005-05-25 PA PA20058634501A patent/PA8634501A1/es unknown
-
2006
- 2006-11-02 IL IL179021A patent/IL179021A/en not_active IP Right Cessation
- 2006-11-03 TN TNP2006000356A patent/TNSN06356A1/en unknown
- 2006-11-07 CR CR8735A patent/CR8735A/es unknown
- 2006-11-15 US US11/559,929 patent/US7833999B2/en active Active
- 2006-11-22 EC EC2006007020A patent/ECSP067020A/es unknown
- 2006-11-23 NI NI200600279A patent/NI200600279A/es unknown
- 2006-12-04 MA MA29510A patent/MA28720B1/fr unknown
- 2006-12-19 NO NO20065918A patent/NO338104B1/no not_active IP Right Cessation
-
2010
- 2010-10-08 US US12/901,063 patent/US8273733B2/en not_active Expired - Lifetime
-
2012
- 2012-08-24 US US13/593,832 patent/US8524700B2/en not_active Expired - Lifetime
-
2013
- 2013-05-24 CY CY20131100411T patent/CY1114240T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8664245B2 (en) | 2009-06-26 | 2014-03-04 | Sanofi | Fumarate salts of a histamine H3 receptor antagonist |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| ECSP067020A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| ES2247527T3 (es) | Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona. | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| CO5650253A2 (es) | Piperazina con grupo fenilo or-sustituido y su uso como inhibidores de glyt1 | |
| CO6251247A2 (es) | Imidazoquinolinas con propiedades inmuno-moduladoras | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| PA8776401A1 (es) | Nuevos compuestos hetericiclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos | |
| AR054335A1 (es) | Procedimiento para aumentar la estabilidad a la oxidacion de biodiesel | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| ES2578628T3 (es) | Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4 | |
| AR109991A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
| MX2019007684A (es) | Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. | |
| AR050266A1 (es) | Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa | |
| ECSP088257A (es) | Derivados de amida | |
| CR7249A (es) | Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo | |
| AR074818A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 | |
| AR052450A1 (es) | Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica | |
| ECSP078009A (es) | Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica | |
| AR072754A1 (es) | DERIVADOS DE DIAZEPAN Y PIPERAZINA COMO MODULADORES DE RECEPTORES DE QUIMIOQUINA Y PROCESOS DE PREPARACIoN |